10:53 AM EDT, 06/11/2025 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said its phase 3 trial of Sotyktu met its primary goal, showing at least 20% symptom improvement in psoriatic arthritis patients by week 16.

About 54% of treated patients saw improvement with a safety profile consistent with previous trials, the company said Wednesday in a statement. The most common side effect was upper respiratory tract infections.

The drug also met multiple secondary goals, including improvements in skin symptoms, physical function and overall disease activity, the company said.

The findings are being presented as a late-breaking abstract at the European Alliance of Associations for Rheumatology Congress in Spain this week.

Price: 50.39, Change: +0.41, Percent Change: +0.83